Related Experiment Video
Updated: Jun 10, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats
Xinxin Yang1, Weien Yuan, Tianan Ren
1Department of Neurology, Xinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Neuroreport
|July 16, 2010
Summary
Biodegradable microspheres loaded with levodopa/benserazide effectively reduced levodopa-induced dyskinesia (LID) in Parkinson's disease rat models. This novel formulation also improved motor function in affected limbs, offering a potential new treatment strategy.
Area of Science:
- Neuroscience
- Pharmacology
- Biomedical Engineering
Background:
- Parkinson's disease (PD) involves progressive loss of dopaminergic neurons.
- Levodopa is a primary treatment for PD but can cause levodopa-induced dyskinesia (LID).
- LID presents as abnormal involuntary movements, complicating long-term PD management.
Purpose of the Study:
- To investigate the efficacy of levodopa/benserazide-loaded biodegradable microspheres in managing PD symptoms.
- To assess the potential of this formulation in reducing LID.
- To evaluate improvements in motor function in a PD rat model.
Main Methods:
- Development of biodegradable microspheres encapsulating levodopa/benserazide.
- Administration of microspheres to a rat model of Parkinson's disease.
- Evaluation of levodopa-induced dyskinesia (LID) expression and motor function (stepping tests).
Main Results:
- Levodopa/benserazide-loaded microspheres significantly reduced LID expression compared to standard levodopa/benserazide administration.
- The microsphere formulation improved stepping ability in the lesioned forepaw of PD rats.
- Biodegradable microspheres demonstrated a therapeutic benefit in a preclinical PD model.
Conclusions:
- Levodopa/benserazide-loaded biodegradable microspheres show promise for treating Parkinson's disease.
- This formulation may offer a strategy to mitigate levodopa-induced dyskinesia (LID).
- Further research into microsphere-based drug delivery for PD is warranted.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...